Giotrif 30 mg

Giotrif 30 mg tablets contain afatinib dimaleate, a targeted therapy used to treat certain types of cancer. This oral medication is designed to inhibit specific proteins involved in cancer cell growth.

Giotrif 30 mg tablets are primarily used in the treatment of non-small cell lung cancer (NSCLC) with specific genetic markers. Afatinib, the active ingredient, works by targeting and blocking proteins that promote cancer cell proliferation. This medication is often prescribed for patients with EGFR mutations, which are commonly found in certain types of lung cancer.

Common effects of Giotrif 30 mg tablets may include skin rash, diarrhea, and nausea. Some users might experience appetite loss or fatigue. These effects can vary in severity and duration, and it's important to monitor any persistent or severe symptoms.

Giotrif 30 mg tablets should be handled with care and stored as directed. It is essential to follow the prescribed dosage and administration instructions provided by a healthcare professional. Patients should inform their healthcare provider about any pre-existing conditions or allergies before starting this medication.

Giotrif 30 mg tablets may interact with certain medications, including those that affect liver enzymes. It is advisable to avoid grapefruit and grapefruit juice, as they can interfere with the metabolism of afatinib. Always consult a healthcare provider before combining Giotrif with other medications.